Novartis AG
NVSHealthcare|Drug Manufacturers - General|Switzerland
$152.84
+0.00 (+0.00%)
DCF (FCF)
$89.99
Earnings Power
$56.11
About
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
Stock Price
+36.1%(1Y)
Pipeline Summary
530 total trials70
Phase 1
173
Phase 2
138
Phase 3
81
Phase 4
Active: 29Completed: 366Recruiting: 25Terminated: 79NOT_YET_RECRUITING: 5ENROLLING_BY_INVITATION: 2Withdrawn: 8NO_LONGER_AVAILABLE: 3APPROVED_FOR_MARKETING: 1Unknown: 9AVAILABLE: 3
Active Trials (54)
Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis
NCT06430671Relapsing-remitting Multiple Sclerosis (RRMS)
Phase 1Active
Enrollment: 11 participants
Detect V / CHEVENDO (Chemo vs. Endo)
NCT02344472Metastatic Breast Cancer
Phase 3Active
Enrollment: 271 participants
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
NCT04111978Ovarian Neoplasm Epithelial
Phase 3Recruiting
Enrollment: 540 participants
The Drug Rediscovery Protocol (DRUP Trial)
NCT02925234Cancer
Phase 2Recruiting
Enrollment: 1,550 participants
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
NCT05017142Optic Neuritis
Recruiting
Enrollment: 500 participants
BioScore
5.2/10
Watchlist
Ownership
Recent News
2026-03-30 20:50:19
2026-03-27 12:44:23
2026-03-27 10:32:31
2026-03-26 18:02:04
2026-03-20 15:45:00
Data last updated: Apr 7, 2026, 01:27 PM